ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0367

Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease

Peri Newman1, Sharon Banks1, Rayford June2, Erik Lehman3, Glennys Smith4, Vandana Rai4, Nicole Wilson4, Nancy Olsen5 and Tarun Sharma4, 1Penn State Health, Hershey, PA, 2Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, 3Penn State College of Medicine, Hershey, PA, 4Allegheny Health Network, Pittsburgh, PA, 5Penn State University/Milton S Hershey, Hershey, PA

Meeting: ACR Convergence 2024

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), practice guidelines, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The 2021 American College of Rheumatology guidelines for treatment of rheumatoid arthritis (RA) conditionally recommend a gradual discontinuation of methotrexate (MTX) over biologic discontinuation. While MTX tapering may be a consideration for some patients, successful implementation will require understanding of patient and provider perspectives on methotrexate reduction. In this study, we aimed to evaluate the perspectives of patients and providers at different stages of practice on MTX tapering in stable RA at two tertiary care centers serving different patient populations.

Methods: After IRB approvals, Allegheny Health Network (AHN-urban) and Penn State Health (PSH-rural) rheumatology providers and RA patients at least 18 years old and on a stable dose of MTX for at least 6 months were surveyed on their perspectives about MTX use and taper. Patient surveys included questions about demographics, health history related to RA and MTX use, and views on tapering and discontinuation of MTX. Provider surveys included questions about years of experience, timing of tapering, and preferred strategies for tapering. All surveys were anonymous. Data were collected in REDCap. Chi square analysis and Wilcoxon rank sum tests were used to analyze stratified data.

Results: Surveys were collected from patients: 73 at AHN and 70 at PSH. They included 112 females (78%) ; 86% were White. Duration of RA was >11 years in 52% and duration of MTX use was >7 years in 50%. Self-assessed RA status ( 0=very well and 10 = poor) was significantly better in White patients (mean score 3.41) than in non-White patients (mean score 5.06; p=0.007). In response to questions about MTX tapering, significant differences were noted in defined subgroups (Table 1). Tapering trials of MTX were more frequent at AHN than PSH (P=0.02) maybe related to medical co-morbidities, were more frequently attempted or considered in males than females (P=0.005, P=0.042, respectively) and in those with > 21 years of disease (P=0.01). Tapering off MTX was more frequent in patients on the drug for at least 8 years than those with < 8 years (P=0.01). However, concerns about risks of reducing or stopping MTX, including flares or worsening, were greater in patients on MTX for at least 8 years (P values 0.0036, 0.00178, 0.00145) and were also greater in females than males (P=0.046). The frequency of skipping MTX was greater in patients < 65 years of age than those older (P=0.024).   Surveys were completed for 16 providers at AHN and 8 at PSH; 42% had been in rheumatology practice for ≥15 years (Table 2). Providers with < 15 years of experience were more likely to consider concurrent DMARD as favorable for tapering MTX (P=0.019) and were also more likely to consider patient preferences against tapering (P=0.004). No significant differences were found between the two provider networks (not shown). 

Conclusion: In our multi-center study, we uncovered patient and provider factors that could influence tapering decisions, including age, race, sex, duration of RA, duration of MTX use, provider’s years of experience, and population-level differences between two different tertiary care centers. Consideration of these factors will facilitate decisions regarding MTX tapering in stable RA.

Supporting image 1

Supporting image 2


Disclosures: P. Newman: None; S. Banks: None; R. June: None; E. Lehman: None; G. Smith: None; V. Rai: None; N. Wilson: None; N. Olsen: Amgen, 5, UCB, 5; T. Sharma: None.

To cite this abstract in AMA style:

Newman P, Banks S, June R, Lehman E, Smith G, Rai V, Wilson N, Olsen N, Sharma T. Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/opinions-from-rheumatoid-arthritis-patients-and-providers-on-discontinuing-methotrexate-in-stable-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/opinions-from-rheumatoid-arthritis-patients-and-providers-on-discontinuing-methotrexate-in-stable-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology